Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer

Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) presents as an unmet clinical challenge for drug delivery due to its unique hypoxic biology. Vinblastine-N-Oxide (CPD100) is a hypoxia-activated prodrug (HAP) that selectively converts to its parent compound, vinblastine, a potent cytotoxic agent, under oxygen...

Full description

Bibliographic Details
Main Authors: Vidhi M. Shah, Craig Dorrell, Adel Al-Fatease, Brittany L. Allen-Petersen, Yeonhee Woo, Yuliya Bortnyak, Rohi Gheewala, Brett C. Sheppard, Rosalie C. Sears, Adam WG. Alani
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Pharmaceutics
Subjects:
hypoxia-activated prodrug
liposome
drug delivery
organoids
pancreatic cancer
Online Access:https://www.mdpi.com/1999-4923/14/4/713

Internet

https://www.mdpi.com/1999-4923/14/4/713

Similar Items